Foghorn Therapeutics (FHTX) Total Liabilities (2019 - 2026)

Foghorn Therapeutics' Total Liabilities history runs 8 years deep, the most recent figure standing at $298.6 million for Q1 2026.

• On a quarterly basis, Total Liabilities fell 6.8% year-over-year to $298.6 million in Q1 2026; TTM through Mar 2026 was $298.6 million, a 6.8% decrease from a year earlier, with the FY2025 full-year figure at $306.6 million, down 6.95% from the prior year.
• Total Liabilities slipped to $298.6 million in Q1 2026 per FHTX's latest filing, from $306.6 million in the prior quarter.
• Across five years, Total Liabilities topped out at $415.9 million in Q1 2022 and bottomed at $294.6 million in Q3 2025.
• The 5-year median for Total Liabilities is $352.5 million (2024), against an average of $355.6 million.
• Across the five-year window, Total Liabilities soared 297.15% in 2022 and decreased 12.49% in 2025, its largest moves.
• Year by year, Total Liabilities stood at $404.8 million in 2022, then fell by 10.29% to $363.1 million in 2023, then decreased by 9.25% to $329.5 million in 2024, then slipped by 6.95% to $306.6 million in 2025, then fell by 2.62% to $298.6 million in 2026.
• Per Business Quant, the three latest FHTX Total Liabilities figures stand at $298.6 million (Q1 2026), $306.6 million (Q4 2025), and $294.6 million (Q3 2025).